<abstract xmlns="http://www.w3.org/1999/xhtml"><p> Olaparib is a potent oral inhibitor of PARP 1 &amp; 2 with biological activity in various solid tumours for patients with germline and/or sporadic BRCA mutations. The aim of this review is to present the results of the various studies which show Olaparib’s efficacy in ovarian cancer</p></abstract>

Olaparib is a potent oral inhibitor of PARP 1 & 2 with biological activity in various solid tumours for patients with germline and/or sporadic BRCA mutations. The aim of this review is to present the results of the various studies which show Olaparib’s efficacy in ovarian cancer

OLAPARIB: A promising PARP Inhibitor for the treatment of ovarian cancer

2nd Oncology Dpt, Cancer Hospital of Kifisia “Oi Agioi Anargiroi”

Oncology Dpt., Department of Clinical Therapeutics at “Alexandra” Hospital, Athens

Director, 2nd Oncology Dpt, Cancer Hospital of Kifisia “Oi Agioi Anargiroi”

Forum of Clinical Oncology

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

{"article-title":"OLAPARIB: A promising PARP Inhibitor for the treatment of ovarian cancer"}

Olaparib is a potent oral inhibitor of PARP 1 & 2 with biological activity in various solid tumours for patients with germline and/or sporadic BRCA mutations....

OLAPARIB: A promising PARP Inhibitor for the treatment of ovarian cancer

Publié en ligne: 17 déc. 2015

Pages: 1 - 7

Reçu: 18 sept. 2015

Accepté: 30 sept. 2015

DOI: https://doi.org/10.1515/fco-2015-0014

Mots clés
PARP-inhibitors, Olaparib, Ovarian Cancer

© 2015

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

OLAPARIB: A promising PARP Inhibitor for the treatment of ovarian cancer

Publié en ligne: 17 déc. 2015

Pages: 1 - 7

Reçu: 18 sept. 2015

Accepté: 30 sept. 2015

DOI: https://doi.org/10.1515/fco-2015-0014

Mots clésPARP-inhibitors, Olaparib, Ovarian Cancer

© 2015

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Mots clés
PARP-inhibitors, Olaparib, Ovarian Cancer